Novotech, Sonic Clinical Trials sign central lab services agreement
Asia Pacific specialist CRO Novotech announced it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare.
Through this partnership, Novotech clients will be able to select from a wide menu of assays or biomarkers, access a trial-specific kit assembly service and use a single clinical trial-dedicated laboratory with a global reach, for priority processing of clinical trial samples.
Announcing the new partnership, Novotech CEO Dr. John Moller said, “Novotech has always focused on offering flexible and cost-effective clinical trial solutions. Through our partnership with Sonic Clinical Trials, our clients will experience a seamless integration of laboratory services and clinical trial data management. From start to finish, our clients are supported by a team of dedicated project managers.
“Another key benefit to our clients is the fact that Sonic Clinical Trials is pre-audited and an approved Novotech vendor. This removes our clients’ need to undertake their own central lab vendor assurance—providing a further savings in cost and clinical trial time.”
Sonic Clinical Trials is also a registered Research Service Provider (RSP) with AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science. “Sonic Clinical Trials’ RSP status assists our eligible international clients when accessing the Australian R&D Tax Incentive Scheme. Research from a recent Frost and Sullivan white paper revealed that eligible companies can conduct early stage clinical trials 60% more cheaply in Australia than the USA,” explained Dr. Moller. “Novotech’s size and Asia Pacific focus allows our clients to enjoy a direct, hands-on approach to accessing some of the largest patient pools in the world but we balance this with providing global gold-standard central laboratory services and data management platforms.”